Sumitomo Pharma America, Inc.
Clinical trials sponsored by Sumitomo Pharma America, Inc., explained in plain language.
US subsidiary of Japanese pharmaceutical company developing treatments for CNS and oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for rare bone marrow cancer Results expected Apr 2027 (estimated)
- New hope for Hard-to-Treat leukemia? enzomenib trial launches Results expected Jun 2027 (estimated)
-
New liposomal drug takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill shows promise for rare bone marrow cancer
Disease control Recruiting nowThis study tests an experimental pill called nuvisertib for people with myelofibrosis, a rare bone marrow disorder. It is for patients whose disease is moderate to high risk and who have not responded well to standard treatments. The goal is to see if the drug is safe and can shr…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Stem cell patch aims to slow vision loss in rare eye disease
Disease control Recruiting nowThis study tests a one-time injection of retinal cells made from stem cells (DSP-3077) into the eye of 12 adults with retinitis pigmentosa, a genetic condition that causes gradual vision loss. The main goal is to see if the treatment is safe and tolerable. Participants are groupe…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for Hard-to-Treat leukemia? enzomenib trial launches
Disease control Recruiting nowThis study tests a new oral drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well it works alone or combin…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could brain cell implants ease Parkinson's? new trial begins
Disease control Recruiting nowThis early-stage trial tests a cell therapy called DSP-1083, implanted directly into the brain, for people with Parkinson's disease. About 25 participants will either get the real implant or a sham surgery to see if it's safe and helps control symptoms. The goal is to replace dam…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug metabolism study launches for stubborn blood cancers
Knowledge-focused Recruiting nowThis study looks at how the body absorbs, breaks down, and gets rid of an experimental drug called DSP-5336. It involves 8 adults with advanced blood cancers (like leukemia or myeloma) that no longer respond to standard treatments. Participants take a single radioactive-labeled p…
Phase 1 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC